Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
deals
2
×
life sciences
national blog main
national top stories
san francisco
san francisco blog main
san francisco top stories
adeno-associated virus
alexandria venture investments
altitude life science ventures
american society of gene and cell therapy
amgen
arch venture partners
boxer capital
cancer
cancer drugs
clinical trials
cobimetinib
dravet syndrome
ed kaye
encoded therapeutics
gene therapy
generation bio
hemophilia
illumina
illumina ventures
investing
ipo
matrix capital management
menlo ventures
new york blog main
new york top stories
regulatory elements
revolution medicines
rna
roche
rtw investments
What
despite
2
×
cancer
crude
cutting
drug
edge
effects
encoded
family
gene
hardest
help
hit
hottest
hunters
illumina’s
ipo
lasting
limited
limits
long
medicine
medicines
nabs
progress
promising
proteins
push
ras
reels
remains
research
revolution
single
targets
therapy
therapy’s
treatment
Language
unset
Current search:
despite
×
deals
×
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
